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Introduction
THE MANNER IN WHICH CREATORS of biopharmaceuticals ap-
proach research and development, product approval, marketing, and
patent protection is undergoing fundamental change in light of new
law. Two relatively recent statutes—one providing for approval of and
resolution of patent disputes concerning biopharmaceuticals, and the
other making changes to basic patent law—outline a new legal frame-
work. Although the parameters of that framework have yet fully to be
defined, it is clear that the new law will require biopharmaceutical
inventors and manufacturers to focus on patent strategies early in the
product planning process by gathering comprehensive information
about relevant existing patents and applications, carefully weighing
the benefits of applying for patent protection and determining the
scope of protection to seek, and considering the consequences of dis-
closure requirements in connection with obtaining regulatory ap-
proval and/or patent protection.
The Biologics Price Control and Innovation Act (“BPCIA”), en-
acted in March 2010, provides for regulatory approval of “follow-on”
biopharmaceuticals and is loosely analogous to the system established
for generic drugs.1 The BPCIA allows for streamlined Food and Drug
Administration (“FDA”) approval of “follow-on biologics.” Follow-on
biologics (“FOBs”) can be approved more quickly and without sub-
stantial investment in clinical trials because they are “highly similar” to
* The authors are attorneys with Kilpatrick Townsend & Stockton LLP. Further
information about the authors and Kilpatrick Townsend & Stockton LLP’s
pharmaceuticals and biopharmaceuticals practice may be accessed at www.kilpatrick
townsend.com.
1. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, §§ 7001–7003,
124 Stat. 119, 804–21 (2010).
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biologic products that have already been approved by the FDA (“refer-
ence biologic products”). The BPCIA also imposes disclosure obliga-
tions that may change the manner in which developers of FOBs
choose to apply for market authorization. Further, it provides proce-
dures for resolving patent infringement disputes that will require de-
velopers of both FOBs and reference biologic products (“RBPs”) to
adopt proactive patent strategies. The BPCIA is aimed at encouraging
development and dissemination of FOBs at lower cost to patients
while protecting investment in innovation.
The America Invents Act (“AIA”), enacted September 16, 2011,
makes significant changes to U.S. patent law that will affect the man-
ner in which developers of RBPs and FOBs address development, ap-
plication for patent protection, and patent disputes. The AIA provides
new procedures intended to improve the quality of U.S. patents and
to transition the national patent system to one that is consistent with
international patent law.2 Among other changes, the AIA provides for
a “first to file” patent priority system, distinguished from the previous
“first to invent” patent priority.3 The AIA also provides revised and
new procedures useful to third parties challenging the validity of U.S.
patents.4 This new legal landscape elevates the importance of careful
investigation and planning at early stages in the process of researching
and developing biologic products.
It remains to be seen whether the BPCIA as implemented, and
along with changes to patent law under the AIA, will achieve its goal
of making biologics cheaper and more widely available while main-
taining incentives for biologic innovation in the United States. This
Article explores the potential consequences of the new legal land-
scape for biologics manufacturers. Part I provides a general introduc-
tion and background concerning (1) the importance of biologics in
the U.S. and global markets and (2) the characteristics of biologic
products. Part II includes: (1) an overview of the law applicable to
follow-on biologics with background on approval pathways other than
that established by the BPCIA, (2) a summary of the important provi-
sions of the BPCIA, and (3) a brief discussion of the FDA’s draft gui-
dance concerning specific implementation of the BPCIA. Part III
summarizes some of the more significant changes to patent law imple-
2. Leahy-Smith America Invents Act, Pub. L. No. 112–29, 125 Stat. 284 (2011).
3. § 3(b), 125 Stat. at 285–87 (amending 35 U.S.C. §§ 102–103).
4. § 3(h)–(i), 125 Stat. at 288–90 (providing derivation proceedings); § 6(d), 125
Stat. at 305–11 (amending post grant review proceedings at 35 U.S.C. §§ 321–329); § 6(a),
125 Stat. at 299–305 (amending 35 U.S.C. §§ 311–319).
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mented by the AIA and discusses how those changes may affect patent
filing strategy, patent prosecution, and resolution of patent disputes
in the context of biologics. Finally, Part IV focuses on the practical
implications of the new framework, for both RBP and FOB
companies.
I. Background
A. General Introduction
Biologics, also known as biological drugs, are pharmaceuticals
made from living sources such as bacteria, viruses, cell culture, or ani-
mals.5 They are one of the most exciting frontiers in therapeutic
healthcare and are projected to play an increasingly important role in
the pharmaceuticals market. Biopharmaceuticals have been proven as
effective therapeutics for diseases and disorders such as colon cancer,
multiple sclerosis, and rheumatoid arthritis. Scientific advances show
great promise for many additional therapies.
Biologics and biopharmaceuticals are one of the fastest growing
and most expensive components of the U.S. prescription pharmaceu-
tical market. Combined sales of the top twelve biologic products in
the United States were around $30 billion in 2010.6 It has been pre-
dicted that by 2014, seven of the top ten pharmaceutical products will
be biologics.7 By 2018, sales of prescription biologic products are ex-
pected to rise to $129 billion, up from $74 billion in 2011.8
As discussed infra, developing and producing a biologic is gener-
ally more expensive and complicated than developing a traditional
small molecule drug. Development costs for an innovator biologic
product (also termed “reference” or “pioneer” biologics) can exceed
$1.2 billion by market launch of the product.9 A biologic innovator
that obtains patent protection, for its biologic and/or the processes
5. See, e.g., Definition of Biological Drug, NAT’L CANCER INST., http://www.cancer.gov/
dictionary?CdrID=426407 (last visited June 8, 2012).
6. ANDREW F. BOURGOIN, THOMPSON REUTERS, WHAT YOU NEED TO KNOW ABOUT THE
FOLLOW-ON BIOLOGIC MARKET IN THE U.S.: IMPLICATIONS, STRATEGIES, AND IMPACT (2011),
available at http://thomsonreuters.com/content/science/pdf/ls/newport-biologics.pdf.
7. See Press Release, EP Vantage, Biotech Set to Dominate Drug Industry Growth
(June 17, 2009), http://www.evaluatepharma.com/Universal/View.aspx?type=Story&id=
188700&sectionID=&isEPVantage=yes (last visited June 21, 2012).
8. EVALUATEPHARMA, SURVEYING TOMORROW’S BIOPHARMA LANDSCAPE: THE NASDAQ
BIOTECH INDEX UP CLOSE 4 (2012).
9. Press Release, PhRMA, PhRMA Statement Supporting Fair Incentives for Biologics
Innovation (Oct. 19, 2010), available at http://www.phrma.org/media/releases/phrma-
statement-supporting-fair-incentives-biologics-innovation [hereinafter PhRMA Press
Release].
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used to create the biologic, is generally able to recoup some of that
investment through patent exclusivity.10 Still, much of the cost is
passed along to the patient. Biologic treatment for a single patient can
cost tens of thousands of dollars annually.11 For example, Avonex®,
which treats multiple sclerosis, has been reported to cost $20,000 per
year; Avastin®, a colorectal cancer therapy, has been reported to cost
$43,000 per treatment course; and Enbrel®, a drug for rheumatoid
arthritis, has been reported to cost up to $25,000 per year.12 Accord-
ingly, there is a demand for more accessible biologics that can be
made available to more patients at a lower cost. The BPCIA was
passed, in large part, as a response to this demand.
B. Follow-on Biologics
The availability of traditional chemical or small molecule
pharmaceuticals in generic form has successfully lowered costs and
made medications more widely available. Generic versions of brand
name innovator chemical drugs—versions of the drug that are proven
to be substantially the same as the original—are widely available at
relatively low cost under the provisions of the Hatch-Waxman Act
(“Hatch-Waxman”).13 Hatch Waxman allows a generic drug maker to
rely on previously submitted safety and efficacy data from the devel-
oper of the brand name drug (often termed the “innovator” or “pio-
neer”).14 A generic drug maker can take advantage of abbreviated
procedures to obtain FDA approval, making generic drugs less expen-
sive than their brand name counterparts. The streamlined procedures
provided under Hatch Waxman are applicable only to pharmaceuti-
cals approved under the Food, Drug, and Cosmetic Act (“FD&C Act”)
and, as such, do not generally apply to biologics.
Given the demand for more widely available and less expensive
biologics, several major world markets (among them, the European
Union and Japan) have instituted systems intended to facilitate ap-
10. Exclusivity refers to a specific number of years during which no one may make,
sell, offer to sell, use, or import the biologic without permission from the innovator/patent
holder.
11. See  “Senators Announce Bipartisan Proposal to Bring Biologic Drugs to Market,
Saving Billions in Medicare Costs,” available at http://www.collins.senate.gov/public/index
.cfm/press-releases?ID=48a978f0-802a-23ad-438c-1d7905e249c0 (last visited June 21,
2012).
12. Id.
13. 21 U.S.C. § 355(j) (2006).
14. See id. (listing the requirements of the abbreviated new drug application, which
substitutes bioequivalence studies for the safety and efficacy studies required in a new drug
application under 21 U.S.C. § 505(b)(1)).
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proval of “biogenerics” or “biosimilars.”15 It is estimated that bringing
follow on biologics to market would save federal healthcare programs
like Medicare and Medicaid at least $10 billion.16 However, as dis-
cussed in detail infra, the complexity of biologics dictates that the le-
gal and regulatory framework for approving a FOB cannot track the
Hatch Waxman provisions for approving generic drugs.
With enactment of the BPCIA, the United States made its own
provision for approval and marketing of FOBs. Global sales of biosimi-
lar products that would be eligible for the new BPCIA FOB approval
pathway are projected to grow to $3.7 billion by 2015 (up from $243
million in 2010).17 This projected market expansion illustrates grow-
ing demand for accessible biologics. The growing market for FOBs is
also attributed to the fact that market exclusivity for many biologics
(under the rules governing FDA application procedures and/or pat-
ent protection) will expire in the next few years, opening the door to
additional manufacturers.18 FDA market exclusivity for the biologic
products Herceptin® (trastuzumab), Remicade® (infliximab),
Rituxan® (rituximab), and Enbrel® (etanercept) expired in 2010; by
2018, Avastin® (bevacizumab), Neulasta® (pegfilgrastim), Humira®
15. Terminology is confusing in this area. What the U.S. law has defined as “follow-on
biologics” (FOBs) may also be variously referred to as “biogenerics,” “biobetters,” “biosimi-
lars,” “subsequent entry biologics” (“SEBs”), or “post-patent biologics.” Indeed, the oft-
used term “biogeneric” is a misnomer. A generic drug is proven to have the “same” active
ingredient and possess the same biological as the brand name product. As discussed infra,
the complex nature of many biologic products may preclude a conclusive demonstration
of such “sameness.” This Article uses the term “follow-on biologic” or “FOB” to avoid con-
fusion and to maintain the distinction that the U.S. law draws between a FOB that is “bi-
osimilar” and a FOB that is “biosimilar” and “interchangeable.” See infra Part IV.
16. See, e.g., Donald Zuhn, President’s Latest Budget Proposal Seeks Decrease of Data Exclu-
sivity Period and Elimination of Pay-for-Delay Agreements, PAT. DOCS (Feb. 21, 2012), http://
www.patentdocs.org/2012/02/presidents-latest-budget-proposal-seeks-decrease-of-data-ex-
clusivity-period-and-elimination-of-pay-f.html.
17. Ben Hirschler, Biosimilars Seen as a $3.7bln Drug Market by 2015, REUTERS (Mar. 28,
2011), http://www.reuters.com/article/2011/03/28/pharmaceuticals-biosimilars-idUSLD
E72R0VR20110328.
18. Id.
A patent owner is generally entitled to twenty years of exclusivity, measured from the
time of patent filing. 35 U.S.C. § 154(a)(2) (2006).
“FDA market exclusivity” refers to the period of time during which the law and/or
FDA regulations provide that the manufacturer who first obtains approval for a particular
pharmaceutical is entitled to be the sole authorized source for that pharmaceutical.
For a discussion on exclusivity, see Frequently Asked Questions on Patents and Exclusivity,
U.S. FOOD & DRUG ADMIN., http://www.fda.gov/Drugs/DevelopmentApprovalProcess/
ucm079031.htm?utm_campaign=Google2&utm_source=fdaSearch&utm_medium=web-
site&utm_term=exclusivity&utm_content=4#How long is exclusivity granted for? (last up-
dated August 29, 2011).
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(adalimumab), and Epogen® (epoetin alfa) also will no longer be en-
titled to market exclusivity.19 Patent protection for most of those prod-
ucts will expire by 2015; Avastin® and Humira® retain patent
protection until 2018 and 2016, respectively.20 Moreover, once FDA
market exclusivity expires, FOB applicants have a substantial incentive
to challenge remaining patent protection.21
C. The Biologics Price Control and Innovation Act
The BPCIA aspires to balance the need to foster investment in
inventing and developing innovator biologics22 with the desire to
make FOBs available to more patients at a reduced cost. The BPCIA
sets out high-level requirements for a streamlined approval pathway
for FOBs and provides an incentive period of market exclusivity for
the first-approved FOB.23 The BPCIA protects the investment of com-
panies who develop and produce reference biologics by providing a
market exclusivity period of twelve years after approval of the refer-
ence product.24 It provides further protection by setting out thorough
procedures for asserting and resolving patent disputes.25 As of the
publication of this Article, the FDA has published draft “guidance”
documents concerning implementation of the BPCIA, and it has ex-
pressly indicated that it will adopt a tiered approach (under which
19. See, e.g., Eye on Innovation, DIALOG (Feb. 2011), http://support.dialog.com/enews
letters/eyeoninnovation/201101/.
20. See Patent Term Extensions, USPTO.GOV, http://www.uspto.gov/patents/resources/
terms/156.jsp (last visited June 29, 2012).
21. Indeed, a robust body of law has developed around generic drug manufacturers’
challenges to patent protection for small molecule pharmaceuticals under the provisions
of the Hatch Waxman Act. A generic manufacturer who wishes to obtain approval under
the Abbreviated New Drug Application (“ANDA”) procedure may file a “Paragraph IV”
certification, stating that its product does not infringe or that the patents covering the
brand name drug are invalid or unenforceable. The advent of FOBs may trigger analogous
litigation although, as discussed in this Article, fundamental differences between biologics
and small molecule drugs—and in the procedures provided by the BPCIA, as opposed to
Hatch Waxman—may result in “higher stakes” litigation with broad scope applicable to
particular categories of biologics and biologic formulations.
22. See supra note 1 at § 7001(b).  Under the BPCIA, an innovator biologic or refer-
ence biologic is the initial version of a biologic compound that is made by what is termed
the “innovator.”
23. 42 U.S.C. § 262(k).
24. 42 U.S.C. § 262(k)(7)(A) (2006 & Supp. IV 2011).The period of market exclusiv-
ity is that period during which no other company may market a FOB for that product.
25. 21 U.S.C. § 355(b)–(c), (j).
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testing requirements can and will be specific to a product or product-
class).26
II. Characteristics of Biologics
Biologics can include nucleic acid compounds, peptides, pro-
teins,27 antibodies,28 blood products, cells, tissues, nucleic acids such
as vectors for gene therapy,29 and small inhibitory ribonucleic acid
(“RNA”) molecules,30 and the like. A biologic may be a purified or
isolated form of a compound that exists in nature.31 For example, a
biologic may be a purified peptide or protein formulated as a thera-
peutic composition. Alternatively, a biologic may be designed to in-
clude specific modifications to proteins found in nature to improve
the stability (half-life) or the pharmacokinetic profile of the biologic
following administration to a patient.
Modifications to a biologic may include amino acid substitutions,
glycosylation (addition of a sugar residue), mutation of reactive sites,
and fusion to other peptides or proteins. Proteins are encoded in na-
26. U.S. DEP’T OF HEALTH & HUMAN SERVS. ET AL, GUIDANCE FOR INDUSTRY: SCIENTIFIC
CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY TO A REFERENCE PRODUCT, DRAFT GUI-
DANCE 4–6–8 (2012), available at http://www.fda.gov/downloads/Drugs/GuidanceCompli-
anceRegulatoryInformation/Guidances/UCM291128.pdf [hereinafter SCIENTIFIC
CONSIDERATIONS].
27. Proteins and peptides are polymers of amino acids linked to each other. Gener-
ally, peptides are shorter polymers (i.e., less than fifty amino acids) than proteins. See, e.g.,
JEREMY M. BERG ET AL., BIOCHEMISTRY 16–23 (W.H. Freeman & Co. 6th ed. 2007).
28. An antibody is a molecule that can react with a component (i.e., often another
protein, a bacteria, or a virus) to provide an immune response. Antibodies have a variety of
structures. The different portions of the antibody molecule have defined sequences and
structure to react either with the foreign component (i.e., the antigen) or the immune
cells of the host.
29. The term “vector” or “plasmid” is used in this Article to describe a vehicle that is
used to transfer genetic material such as DNA sequences from a donor organism to the
target cell of the recipient organism (i.e., from a donor cell to the types of cells that will be
cultured to produce a biologic). See, e.g., Vector, BIOLOGY ONLINE, http://www.biology-on-
line.org/dictionary/Vector (last visited Dec. 26, 2011); Plasmid, BIOLOGY ONLINE, http://
www.biology-online.org/dictionary/Plasmid (last visited Dec. 26, 2011).
30. Small interfering ribonucleic acid (“siRNA”) molecules are RNA molecules that
have the ability to bind to certain cites on messenger RNA so as to result in degradation of
the mRNA and inhibition of expression of the gene. Andrew J. Hamilton & David C.
Baulcombe, A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants, 286
SCIENCE 950 (1999).
31. See, e.g., U.S. DEP’T OF HEALTH & HUMAN SERVS. ET AL., GUIDANCE FOR INDUSTRY:
QUALITY CONSIDERATIONS IN DEMONSTRATING BIOSIMILARITY TO A REFERENCE PROTEIN PROD-
UCT, DRAFT GUIDANCE 14 (2012), available at http://www.fda.gov/downloads/Drugs/Gui-
danceComplianceRegulatoryInformation/Guidances/UCM291134.pdf [hereinafter
QUALITY CONSIDERATIONS] (discussing methods for producing biologics and biosimilars).
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ture by an individual’s deoxyribonucleic acid (“DNA”). This type of
biological synthesis can be replicated in the laboratory by using partic-
ular cell lines, inserting a desired sequence of nucleotides (encoded
to catalyze production, or “expression,” of a desired protein), and
thus engineering recombinant DNA constructs capable of synthesiz-
ing the protein of interest.
Unlike a small molecule drug, which is generally defined by its
chemical composition, a biologic is largely defined by its method of
manufacture—typically synthesis by a living cell using the cell’s DNA,
RNA, and protein synthesis machinery.32 For example, protein thera-
peutics (the most common biologics) are often produced using re-
combinant genetic techniques, through which the specific
characteristics of the protein may be altered at various stages of the
manufacturing process.33 Using these techniques generally entails iso-
lating a DNA sequence encoding the desired protein.34 Then intro-
ducing it into a host cell, which may be a bacterium, yeast, or
mammalian cell,35 by using an appropriate vector (i.e., plasmid vector,
transposon vector, or viral vector).36
Producing a biologic for the market requires scaling up the cell
culture used for production by culturing many liters of cells in condi-
tions under which the cells produce high levels of the desired pro-
tein.37 Variations in the methods of culturing the host cells or
processing the cell culture medium may affect the therapeutic charac-
teristics of the resulting biologic protein. The protein produced by
the cell culture is then tested to ensure the purity and homogeneity of
the molecular structure. For example, changing the nature of the cells
used, or the cell culture medium, can result in differences in how a
32. See, e.g., id. at 4 (comparing small molecule drugs to protein products).
33. Id.
34. See 3 JOSEPH SAMBROOK & DAVID W. RUSSELL, MOLECULAR CLONING: A LABORATORY
MANUAL §§_11.38–.98_(3d ed. 2001) [hereinafter SAMBROOK & RUSSELL: MOLECULAR CLON-
ING]; see also JOSEPH SAMBROOK & DAVID W. RUSSEL, THE CONDENSED PROTOCOLS FROM Mo-
lecular Cloning: A Laboratory Manual 599–620 (2006).
35. For example, Chinese Hamster Ovary (CHO) cells are often used to make mam-
malian proteins.
36. A viral vector is a vector that utilizes viral sequences, at least in part, for replication
and/or expression of the DNA of interest. See, e.g., Philip M. Arlen et al., Vaccines for the
Treatment of Cancer, in HANDBOOK OF ANTICANCER PHARMACOKINETICS AND PHARMACODYNAM-
ICS 457, 461 (William D. Figg & Howard L. McLeod eds., 2004). A transposon vector is a
vector that uses transposon sequences to insert the DNA which may encode the biologic
protein of interest into a genome. See, e.g., GEORGE P. RE´DEI, ENCYCLOPEDIA OF GENETICS,
GENOMICS, PROTEOMICS AND INFORMATICS 2023 (3d ed. 2008).
37. See generally BJORN K. LYDERSEN, LARGE SCALE CELL CULTURE TECHNOLOGY (1993)
(discussing methods of large scale cell culture used in biotechnology).
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particular protein is modified (i.e., by glycosylation and/or other
modifications).38 Such changes may be silent (not detected in terms
of the biological function of the molecule) or may result in significant
alterations in the structure and/or biological activity of the protein.
Also, at least some degradation may occur due to instability of the
protein in culture or during the purification process.39
Methods used for formulation of a biologic in a form for use as a
therapeutic agent also may significantly affect the stability and/or effi-
cacy of the biologic. For example, a protein biologic may be provided
as a lyophilized (freeze-dried) formulation. However, finding mix-
tures of components that preserve the stability and/or activity of a
complex molecule, such as a protein in this state, may require signifi-
cant testing.40 In contrast, formulations for small molecule com-
pounds tend to be far less unpredictable.41
A. A Biologic May Be Highly Complex
Biologics are typically far larger and more complex than small
molecule chemical drugs. Small molecule drugs are often organic
compounds with a molecular backbone ranging from three to ten at-
oms of carbon (in some cases including nitrogen, sulfur, and/or oxy-
gen atoms) with side chains comprised of carbon, nitrogen, oxygen,
and hydrogen. Small molecule therapeutics are generally single mo-
lecular units with a limited number of reactive sites per molecule. In
contrast, biologics are often polymers (chains of multiple molecules),
with multiple, and often complex, subunits.42
The added complexity of biologics introduces far more potential
for variation and a corresponding decrease in predictability of the ef-
fects of modifications to the biologic. For example, a monoclonal an-
38. For example, certain cell lines may naturally produce enzymes that can cleave the
protein of interest at certain sequences in the protein molecule. Also, certain cell lines may
have enzymes that can be activated if a protein is glycosylated (i.e, has a sugar residue) at a
certain position.
39. Testing for whether such degradation has occurred may be performed by experi-
ments to measure the size of the protein(s) produced by the cell culture. Degradation
products (which are smaller than the full-length protein) are detected as smaller contami-
nants. See 3 SAMBROOK & RUSSELL: MOLECULAR CLONING, supra note 34, § 17.78.
40. See, e.g., QUALITY CONSIDERATIONS, supra note 31, at 14.
41. Factors important to the stability of smaller molecules are not, however, trivial.
Such factors may include crystal structure and the solvate (e.g., NaCl vs. water) used to
form the crystals and whether such salts are interchangeable as well as the presence of
polymorphs and other modifications of the chemical structure.
42. See, e.g., QUALITY CONSIDERATIONS, supra note 31, at 4 (comparing small molecule
drugs to protein products).
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tibody may include about 1500 amino acids, some of which could be
modified and/or substituted with a similar amino acid (for example,
an alanine for valine substitution) without significantly altering the
pharmacological activity of the antibody. On the other hand, a rela-
tively small modification, such as glycosylation (addition of a sugar
molecule) at a specific amino acid, may have significant effects such as
increasing or decreasing the stability of the antibody in vitro (as for-
mulated and sold) or in vivo (in cell-culture during production or in a
patient).
B. Achieving and Establishing Sufficient “Similarity” to a
Reference Biologic Product May Be Difficult
It is readily apparent that development of a FOB is not as simple
as developing a generic, small molecule drug. Developing a generic,
small molecule drug is straightforward. The process entails chemical
synthesis by a known and precise method to create, purify, and formu-
late a drug with a known formula in a suitable and stable dosage
form.43 Safety and efficacy can be established by verifying that the ac-
tive ingredient is chemically identical to the active ingredient in the
brand name drug.44
Ensuring that a FOB has the same, or sufficiently similar struc-
ture, stability, and biological activity as a RBP may require much the
same level of effort as developing the RBP. Because the synthesis of a
biologic utilizes complex biological systems, it is expected that
changes to any of the steps used for synthesis (i.e., modifications to
the protein sequence, cells, and/or culture conditions) would lead to
a need for substantial testing to verify that changes to any of the re-
quired steps do not adversely affect the structure and activity of the
FOB.
To characterize a proposed FOB accurately, an applicant must
identify its sequence and three-dimensional structure. The applicant
must also analyze whether and how any differences in sequence or
three-dimensional structure between the FOB and the RBP will affect
the FOB’s pharmacological activity, or its safety. It is critical that the
applicant identifies any change in a FOB—including a substitution of
a single amino acid in a complex protein—and test the FOB to deter-
mine whether the change affects pharmacological activity or safety.
Analyzing the nature of a RBP, or the effect of any change between
43. Id.
44. See infra Part III.B (discussing the ANDA approval process).
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the RBP and a FOB, will require a variety of tests, potentially including
amino acid or nucleic acid sequencing, mass spectrometry, testing of
immunogenicity and toxicity in vivo, stability and binding studies in
vitro, and pharmocokinetic testing.
A peptide or protein comprises a particular sequence of amino
acids. Any change in that sequence will change the primary structure
of the protein and may significantly affect the manner in which the
protein functions.45 A peptide (simple protein), for example, may be
comprised of four amino acids: methionine (M); alanine (A); proline
(P); and isloleucine (I). However, a peptide having the sequence M-A-
P-I could be entirely different in structure and function than a pep-
tide having the sequence I-P-A-M. Thus, determining the composition
and structure of a protein requires the chemical characterization of
the component amino acids in sequence (“sequencing”) and identifi-
cation of the composition and location of molecules that may be at-
tached to those component amino acids.
Studies must be performed to determine how the biologic will
function when administered to a patient. Whether a biologic will bind
to its intended effector molecule (i.e., a receptor or other reactive
molecules) can be determined through in vitro tests so as to measure
binding affinity of the biologic for its target.46 Pharmacokinetic test-
ing is performed to determine the rate of breakdown of the biologic
in the patient. These tests are used to determine the effective concen-
tration, dose, and duration of treatment.47 Immunogenicity—the ex-
tent of a patient’s immune response to administration of the
biologic—must also be considered and may be predicted by perform-
ing tests in animals,48 although a conclusive determination of immu-
nogenicity in humans may require substantial clinical testing.49
To determine whether a proposed FOB is sufficiently similar to
the RBP so as to benefit from testing that has established safety and
efficacy of the RBP, the FOB must be evaluated under conditions of
cell culture used for production and processing similar to what was
required for the reference biologic. This is complicated by the fact
that the RBP innovator is unlikely to share its master cell bank. The
aspiring FOB manufacturer may use different cells, but nonetheless
must develop cell culture conditions that result in high levels of pro-
45. See, e.g., SCIENTIFIC CONSIDERATIONS, supra note 26, at 4–5.
46. Id. at 12.
47. SCIENTIFIC CONSIDERATIONS, supra note 26, at 15.
48. See, e.g., id. at 13–14.
49. See id. at 14–16.
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duction of a stable and pure form of the FOB that performs in a man-
ner “highly similar” to the RBP.
Moreover, a FOB developer has an incentive to try to “design
around” the innovator’s patent protection—that is, to attempt to
make a minor change to its processes and/or FOB to avoid infringing
on the innovator’s patent rights to the FOB itself or to the method of
making the FOB. In the context of biologic products, such relatively
minor changes may fundamentally affect the therapeutic properties of
the FOB. Those changes could result in improved therapeutic proper-
ties (i.e., improved pharmacokinetics or stability), but just as easily
could cause problems—untoward effects such as unanticipated im-
mune responses.
FOBs that can be made available to the public relatively quickly at
an affordable price by avoiding lengthy and expensive development
and testing, may, at least for more complex biologics, be an elusive
goal. The approval process for FOBs cannot be defined in terms of
bright line, “one fits all” rules because a single biologic protein is a
compilation of individual amino acids, some of which are essential to
therapeutic activity and safety, and others of which may be changed
without affecting efficacy or safety. The BPCIA recognizes this compli-
cation and grants the FDA broad discretion both to determine what
proposed products may be eligible for the FOB application process
and what types and amounts of test data will be required to support an
application.50 The FDA has indicated that application eligibility and
requirements will vary by product class.51 It is possible that FOB appli-
cations will not be permitted for some classes of biologic products
where concerns about potential health and safety risks outweigh the
desirability of increasing product availability or accessibility.52
III. Overview of Previous Approval Routes Available for
Some Biological Pharmaceuticals
A. Initiating the Approval Process
The approval process for a NDA and Biologics License Applica-
tion (“BLA”) begins with an Investigational New Drug Application
(“IND”) designed to impose analytical, nonclinical, and clinical re-
search requirements that support the compound’s safety and effi-
50. See 42 U.S.C. § 262(k)(3) (2006 & Supp. IV 2011).
51. See id. § 262(k)(8); see also SCIENTIFIC CONSIDERATIONS, supra note 26.
52. See 42 U.S.C. § 262(k)(8).
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cacy.53 An applicant must analyze and characterize the composition
and structure of the compound.54 The compound is then tested, both
in vivo (within an intact organism) and in vitro (in solution or within
cultured cells of relevant animal species), to evaluate bioavailability,
toxicity, and other functional characteristics.55
A compound that demonstrates therapeutic potential and safety
in animal studies is subsequently studied in humans.56 Human clinical
trials are subject to strict parameters and proceed in several phases.57
Phase I trials administer the compound to healthy subjects to deter-
mine its safety in humans.58 Phase II trials administer the compound
to patients with a specific condition or disease to determine its thera-
peutic effect, safety, and lack of harmful side effects.59 Phase III trials
establish the therapeutic efficacy of the compound.60 This phase of
studies includes a larger number of patients, and the compound is
typically administered to several groups of patients with the specific
condition or disease over defined periods of time.61 If the FDA finds
the data from Phase I, II, and III trials to be acceptable, the com-
pound will be approved for marketing.62 Post-marketing evaluation—
Phase IV studies—is used further to assess whether the compound is
an effective treatment, to track patient outcomes and to identify and
assess any side effects or safety risks.63
The detailed and extensive studies required to support an IND
application require large investments of time and money. A com-
pound is not generally available to patients until Phase III trials are
complete, which may take over ten years.64 Accelerating the market-
ing approval process where feasible would make beneficial com-
pounds sooner available to patients. Streamlining research and
investigation requirements likewise benefits patients—lower develop-
ment costs would ostensibly lead to lower prices.
53. 21 U.S.C. § 355 (2006).
54. Id. § 355(b)(1).
55. Id. § 355(b)(1)(A).
56. Development & Approval Process (Drugs), supra note 18.
57. Understanding Clinical Trials, CLINICALTRIALS.GOV, http://clinicaltrials.gov/ct2/
info/understand (last updated Sept. 20, 2007).
58. 21 C.F.R. § 312.21 (2011).
59. Id.
60. Id.
61. Id.
62. Understanding Clinical Trials, supra note 57.
63. 21 C.F.R. § 312.85.
64. Steven M. Paul et al., How to Improve R&D Productivity : The Pharmaceutical Industry’s
Grand Challenge, 9 NATURE REVS. DRUG DISCOVERY 203, 211 (2010).
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B. Federal Food, Drug and Cosmetic Act Versus Public Health
Services Act
The data collected during the IND process is used to support a
NDA or a BLA. A NDA is filed under the Federal Food, Drug, and
Cosmetic Act (“the FD&C Act”); however, a biologic can be approved
under both the FD&C Act65 or the Public Health Services Act
(“PHSA”).66 These two acts are different. The FD&C Act applies to all
drugs and medical devices, while the PHSA applies to biological prod-
ucts.67 The FDA administers both statutes.68
A NDA allows for marketing approval for a pharmaceutical cov-
ered by the FD&C Act.69 A BLA allows for approval of a new biologic
regulated by the PHSA.70 Accelerated approval pathways for NDA ap-
proved products are available for (1) “generic” products that are
proven through an Abbreviated New Drug Application (“ANDA”) ap-
plication to be the “same” as the previously approved product; and (2)
modifications of the previously approved product that are shown
through a section 505(b)(2) application to be appropriately sup-
ported by the FDA’s findings with respect to the previously approved
product.71
Historically, there has been some overlap between biologics sub-
ject to the PHSA and drugs regulated under the FD&C Act.72 “On
June 30, 2003, the FDA transferred some of the therapeutic biological
products that had been reviewed and regulated by the Center for Bio-
logics Evaluation and Research (“CBER”) to the Center for Drug Eval-
uation and Research (“CDER”).”73 CDER is responsible for the
following categories of biologics: monoclonal antibodies for in vivo
use; most proteins intended for therapeutic use; immunomodulators;
65. 21 U.S.C. §§ 301–399D (2006).
66. 42 U.S.C. § 262 (2006 & Supp. IV 2011).
67. 21 U.S.C. § 393; 42 U.S.C. § 241.
68. 21 U.S.C. § 393; 42 U.S.C. § 241 (providing that the Secretary of the Department
of Health and Human Services is responsible, acting through the FDA Commissioner, for
executing the FD&C Act).
69. 21 U.S.C. § 355(b)(1).
70. 42 U.S.C. § 262.
71. 21 C.F.R. § 320.24 (2011).
72. Human Drugs Which Are Biological Products, Redelegation of Authority to Ad-
minister Certain Provisions of the Federal Food, Drug, and Cosmetic Act, 37 Fed. Reg.
4004, (Feb. 25, 1972).
73. Transfer of Therapeutic Products to the Center for Drug Evaluation and Research, U.S.
FOOD & DRUG ADMIN., http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedical
ProductsandTobacco/CBER/ucm133463.htm (last updated Feb. 22, 2010).
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growth factors; and cytokines.74 Other biologics, including cellular
products, gene therapy products, vaccines, allergenic extracts, antitox-
ins, blood, and blood components, remain under CBER.
C. Accelerated Approval Pathways Before the Biologics Price
Competition and Innovation Act
Before passage of the BPCIA, the law provided two accelerated
routes to approval of compounds for which it can be shown that previ-
ous studies in connection with an NDA. Hatch Waxman provides for
an ANDA75 for generic versions of pharmaceuticals regulated under
the FD&C Act, and Section 505(b)(2) of the FD&C Act provides a
somewhat accelerated application process for pharmaceuticals that
may not be eligible for an ANDA.76
1. Abbreviated New Drug Application
To qualify for ANDA approval, an applicant must show that the
proposed product (the generic) is a pharmaceutical equivalent to the
product that was approved under the full NDA application proce-
dure—i.e., subject to the IND requirements (the “brand name,” “ref-
erence,” “pioneer,” or “innovator” product).77 The statute speaks in
terms of “sameness” and contemplates that a generic product ap-
proved by the ANDA process will be essentially identical to the refer-
ence product.78 An ANDA applicant must provide chemical and
bioequivalence data showing that its product has the same amount of
the same active ingredient in a dosage form that makes the active in-
gredient “bioavailable” (released within the patient) at the same rate
and to the same extent as the product already approved by the FDA.79
If in vivo and in vitro studies support that the bioavailability and purity
levels of the ANDA applicant’s formulation of the active ingredient
are the “same” (within tightly defined acceptable limits), the products
74. Frequently Asked Questions About Therapeutic Biological Products, U.S. FOOD & DRUG
ADMIN., http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevel-
opedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm113522.
htm (last updated Dec. 24, 2009).
75. An Abbreviated New Drug Application (“ANDA”) contains data that permits the
approval of a generic, or bioequivalent, drug. Abbreviated New Drug Application (ANDA):
Generics, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/Drugs/DevelopmentApproval
Process/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNew
DrugApplicationANDAGenerics/default.htm (last updated Jan. 3, 2012).
76. 21 U.S.C. § 355 (2006).
77. 21 C.F.R. pt. 320 (2011).
78. Id.
79. Id.
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will be treated as therapeutically equivalent.80 The ANDA applicant
can then rely on preclinical and clinical trials that established safety
and efficacy of the brand name product.81 A generic drug approved
under the ANDA process will be automatically substitutable for the
brand name product without physician intervention.82
2. Section 505(b)(2)
Section 505(b)(2) was added to the FD&C Act in 1984 to avoid
duplicative testing and Phase III human studies for products that are
reformulations or combinations of existing approved drugs.83 A prod-
uct may be approved by the 505(b)(2) “paper NDA” pathway if it is
shown to be largely the same as products that have already completed
the NDA process.84 Section 505(b)(2) is applicable to proposed modi-
fications of previously approved “drugs,” broadly defined, and unlike
ANDA provisions, does not require proof that the product applied for
is the “same” as the reference product.85 Modifications for which
505(b)(2) approval may be sought include changes in dosage form,
indication or formulation, and extend to changes in active ingredients
where only limited clinical data is necessary to show that the product
incorporating the changed ingredient is therapeutically equivalent to
the product that is already approved.86 Products eligible for the
505(b)(2) process include biologics that were initially approved
through an NDA.87 The amount of data required to support a
505(b)(2) application varies according to the product modification at
issue, but the 505(b)(2) approval pathway generally falls somewhere
between onerous NDA requirements and a streamlined ANDA
showing.88
80. 21 C.F.R. § 320.24.
81. Id.
82. U.S. DEP’T OF HEALTH & HUMAN SERVS. ET AL., APPROVED DRUG PRODUCTS WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS (2012), available at http://www.fda.gov/cder/or-
ange/obannual.pdf [hereinafter ORANGE BOOK].
83. U.S. DEP’T OF HEALTH & HUMAN SERVS. ET AL, GUIDANCE FOR INDUSTRY: APPLICA-
TIONS COVERED BY SECTION 505(B)(2), DRAFT GUIDANCE (1999), available at http://www.fda.
gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM07
9345.pdf [hereinafter APPLICATIONS COVERED BY 505(B)(2)].
84. Id.
85. Id.
86. 21 C.F.R. § 314.54.
87. Id. § 314.3(b); see Abbreviated New Drug Application Regulations, 54 Fed. Reg.
28,872 (July 10, 1989) (to be codified at C.F.R. pts. 10, 310, 314, 320).
88. APPLICATIONS COVERED BY 505(B)(2), supra note 83.
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An applicant must demonstrate the “relevance and applicability”
of the FDA’s findings with respect to the reference product. Depend-
ing on the product at issue, the FDA may also require the applicant to
provide clinical data, including data from human trials, to show that
any differences do not affect therapeutic efficacy or safety.89 Success-
ful applicants under section 505(b)(2) are entitled to market exclusiv-
ity of three to five years.90 The length of market exclusivity granted
depends on the nature of the product modification that was approved
and the amount of clinical data supporting such modification.91
D. Pre-Biologics Price Competition and Innovation Act Approval
Routes for Modification of Products Approved Under a
Biologics License Application
1. Supplemental Biologics License Application
A reference biologic is approved on the basis of the information
required to support a BLA—that is, data concerning the structure and
composition of the biologic and its method of manufacture, pre-
clinical studies, clinical studies, and labeling. After obtaining that ap-
proval, a biologics manufacturer can seek approval for new indica-
tions (new therapeutic uses), labeling changes, or changes in the
method of manufacture by submitting a Supplemental Biologics Li-
cense Application (“sBLA”). sBLAs are also used to seek approval for
post-marketing studies or to submit additional safety or efficacy data
for FDA review.
The regulation providing for sBLAs classifies changes according
to the degree to which they might be expected to affect the therapeu-
tic efficacy and safety of a biologic. Some changes require FDA ap-
proval before any modified product (which includes product
manufactured by a modified process) may be distributed; other
changes simply require reporting to the FDA in a special submission
or in an annual report. Changes requiring submission and approval of
an sBLA, which must be supported by testing and data over and above
what was originally submitted to support the BLA, include “any
change in the product, production process, quality controls, equip-
ment, facilities, or responsible personnel that has a substantial poten-
tial to have an adverse effect on the identity, strength, quality, purity,
or potency of the product as they may relate to the safety or effective-
89. Id.
90. 21 U.S.C. § 355(j)(5)(F) (2006).
91. Id.
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ness of the product.” Specific examples of such changes include
changes to product components (active or inactive ingredients),
changes to specifications for use of the product in its previously ap-
proved applications, changes in the source tissue or cell, establish-
ment of a new master cell bank, and changes in product purification
and sterilization procedures.
2. Product “Comparability”
The FDA issued guidance on a “comparability” standard that ap-
plicants may use to establish efficacy, safety, purity, and potency with-
out conducting a full battery of tests and studies that would otherwise
be necessary to support approval of a product that is not “compara-
ble” to a previously approved product.92 If the FDA determines that a
proposed modification results in a product that is “still safe, pure, and
potent,” then the modified product is sufficiently “comparable” to be
distributed.93
In practice, there is some uncertainty about what is required to
demonstrate the requisite comparability. The FDA’s 1996 “Guidance
Concerning Demonstration of Human Biological Products, Including
Therapeutic Biotechnology-derived Products” explicitly notes that a
manufacturer may demonstrate “product comparability,” between a
biologic made after a modification and a biologic made before the
change was implemented, “through different types of analytical and
functional testing, with or without preclinical animal testing.”94 The
FDA’s guidance describes types of analytical and functional testing,
the results of which “determine the extent of additional tests needed,”
and further notes:
In cases where a manufacturing change(s) results in a prod-
uct with structural and/or bioactivity differences, and/or differ-
ences in pharmacokinetics patterns, and those differences are
meaningful with respect to potential impact on a product’s safety,
purity, or potency (efficacy), an additional clinical study(ies) usu-
ally may be needed to evaluate the product’s safety and/or efficacy.
Additionally, when the analytical and other preclinical testing is
not sufficiently sensitive or broad enough to detect such meaning-
ful differences, additional clinical study(ies) may be needed.95
92. U.S. FOOD & DRUG ADMIN. . DEMONSTRATION OF COMPARABILITY OF HUMAN BIO-
LOGICAL PRODUCTS, INCLUDING THERAPEUTIC BIOTECHNOLOGY-DERIVED PRODUCTS (1996),
available at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/
Guidances/ucm122879.htm.
93. Id.
94. Id.
95. Id.
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The FDA reserves the right to determine instances in which no
clinical studies are necessary, but “[i]n other instances, the FDA may
determine, on the basis of comparability data, that a clinical efficacy
study(ies) is necessary.”96
IV. Approval Under Section 351(k) – The Biologics Price
Competition and Innovation Act
A. Section 351(k) and Implementing Guidelines
The BPCIA—intended to provide a streamlined pathway for ap-
proval of FOBs and to address commercial and patent exclusivity is-
sues—was enacted on March 23, 2010 as Section 351(k) of the
PHSA.97 The BPCIA opens the door to an accelerated and less bur-
densome approval process for FOB applicants. It permits reliance on
data used to support the RBP application with proof of sufficient simi-
larity to justify extrapolating the RBP data to the FOB.98 In this man-
ner, the BPCIA is analogous to the Hatch Waxman provisions for
generic drugs. However, just as biologic products differ from small
molecule pharmaceuticals, the BPCIA pathway is significantly differ-
ent from the Hatch Waxman provisions in terms of approach and
timing.
Under the Hatch Waxman framework, the FDA rates generic
drugs as “therapeutically equivalent” to a previously approved drug if
the applicant establishes that the generic is both (1) bioequivalent
and (2) pharmaceutically equivalent, to the reference drug.99 The
testing necessary to demonstrate these standards is well known and
fairly predictable. Based on the results of this testing, the FDA assigns
each pharmaceutical a therapeutic equivalence designation that indi-
cates the level or degree of “therapeutic equivalence.”100
The standard and testing necessary to show “therapeutic equiva-
lence” of a FOB, on the other hand, is not predictable. The FDA has
broad discretion to control the approval pathway for specific FOBs, or
defined classes of FOBs, and is expected to implement final guidelines
in the very near future.101 The FDA’s recent draft guidelines shed
light on the tiered, product specific approach the FDA intends to ap-
96. Id.
97. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, §§ 7001–7003,
124 Stat. 119, 804–21 (2010).
98. 42 U.S.C. § 262(k)(2)–(4) (2006 & Supp. IV 2011).
99. See ORANGE BOOK, supra note 82, at vii.
100. Id. at xiii–xix.
101. See 42 U.S.C. § 262(k)(8).
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ply to approval of FOBs.102 However, many key issues remain unclear
in light of the draft guidance. These issues include the scope of analyt-
ical, preclinical, and clinical trial data required to support a FOB ap-
plication for particular products or product classes; the actual burden
of post-marketing risk management and tracking plans for data dem-
onstrating long-term safety and addressing immunogenicity; and the
FDA’s definition of equivalence, in terms of the “biosimilar” and “in-
terchangeable” standards set out in the statute. It also remains unclear
what the standard for finding patent infringement will be and how
data and market exclusivity will be applied for the RBP innovator and
the FOB applicant. In addition, the FDA still must establish particular-
ized procedures for maintaining the confidentiality of the FOB appli-
cant’s particularized information about its proprietary manufacturing
processes, which are required to be disclosed to the RBP innovator. It
is possible that at least some of these issues will be addressed once this
new biologic approval pathway begins to be used by FOB applicants.
B. “Biosimilar” and “Interchangeable”
A FOB can be approved for marketing under the BPCIA if it is
proven to be (1) “biosimilar” to or (2) “interchangeable” with the
RBP.103 A product is “biosimilar” if it is “highly similar to the refer-
ence product, notwithstanding minor differences in clinically inactive
components,”104 and “there are no clinically meaningful differences”
between the proposed FOB and the RBP “in terms of the safety, pu-
rity, and potency of the product.”105 A product is “interchangeable” if
it is biosimilar to the RBP and can be expected to produce the same
result in any given patient as the RBP.106 Interchangeability requires
that the risk of switching between the RBP and the FOB must not be
any greater than the risk of using the RBP alone.107
1. “Biosimilar”
A FOB applicant must first establish that its proposed product is
sufficiently similar to the RBP to warrant licensure under section (k)
application process.108 Analytical studies that demonstrate similarity of
102. See, e.g., SCIENTIFIC CONSIDERATIONS, supra note 26.
See, e.g., id.
103. 42 U.S.C. § 262(k)(2)–(4).
104. Id. § 262(i)(2)(A).
105. Id. § 262(i)(2)(B).
106. Id. § 262(k)(4)(A)(i)–(ii).
107. Id. § 262(k)(4)(B).
108. Id. § 262(k)(2)–(4).
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a protein in terms of component amino acids and protein structure
will likely fulfill this requirement.109 The BPCIA explicitly contem-
plates that the FDA may determine that a particular proposed FOB, or
even any proposed FOB in a particular class of products, is ineligible
for consideration if “science and experience” support that
conclusion.110
Once the sufficient similarity is demonstrated as to the RBP’s
composition and structure, animal studies may then be required in
order to demonstrate toxicity (or lack thereof) and bioavailability of
the FOB.111 The FDA also may require human clinical studies to evalu-
ate pharmacokinetics in patients and to address immunogenicity con-
cerns.112 Sufficient data must be provided to the FDA to demonstrate
that the safety, purity, and potency of the FOB is “highly similar” to
that of the RBP for at least one of the uses for which the RBP is au-
thorized (and for which the FOB is proposed to be used).113 Notably,
the FDA may opt to waive requirements for analytical, preclinical, or
clinical studies for any particular FOB application.114 The FDA indi-
cated that it expects a science-driven determination as to which re-
quirements are necessary for particular FOBs.115 This gives rise to
uncertainty because it means that requirements for demonstrating
similarity will be determined on a case-by-case basis.
Establishing that a proposed FOB is “highly similar” to a RBP, in
order to establish that the FOB is “biosimilar” under the BPCIA, re-
quires also that sufficient data is provided to show that:
• The FOB and the RBP use the same “mechanism or mecha-
nisms of action” for the conditions of use for which the FOB is
proposed (with the caveat that this requirement applies only
to the extent that science is able to determine the mechanism
of action for the RBP and FOB);116
109. These analytical studies may include, for example, sequencing analyses, biochemi-
cal analyses, and immunochemical analyses.
110. 42 U.S.C. § 262(k)(8)(E)(i)–(iii).
111. Id. § 262(k)(2)(A)(i)(I)(aa)–(bb).
112. Id. § 262(k)(2)(A)(i)(I)(cc). The draft guidance suggested that the need for and
scope of clinical studies required may depend on the uncertainty left regarding the bi-
osimilarity of the FOB to the RBP in light of the data from the structural and animal
studies. See SCIENTIFIC CONSIDERATIONS, supra note 26, at 12.
113. See 42 U.S.C. § 262(k)(2)(A)(ii).
114. Id.
115. Margaret A. Hamburg, Comm’r of Food & Drugs, Remarks at the Generic Phar-
maceutical Association Annual Meeting (Feb. 18, 2010), available at http://www.fda.gov/
NewsEvents/Speeches/ucm201833.htm.
116. 42 U.S.C. § 262(k)(2)(A)(i)(II).
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• The FOB is proposed for conditions of use for which the RBP
has been approved;117
• The FOB is proposed for the same route of administration,
dosage form, and strength (concentration) as previously ap-
proved for the RBP;118 and
• The FOB is manufactured in a facility that meets FDA stan-
dards for safe, pure, and potent manufacture of biologics.119
These data provide the FDA with sufficient information to predict
whether the FOB will likely be safe for the proposed use. The FDA still
requires that additional data be provided to establish that a FOB is
interchangeable with the RBP.
2. “Interchangeable”
Establishing that a “biosimilar” proposed FOB is “interchangea-
ble” will require additional preclinical and clinical studies in all cases,
except where the RBP and proposed FOB can be demonstrated to be
identical in composition and structure.120 As discussed in Part I.B,
demonstrating “sameness” of composition and structure is challeng-
ing in the context of biologics, for which any small change in composi-
tion, structure, inactive components, and/or conditions of
manufacture, formulation, handling, or storage may affect the thera-
peutic activity of the pharmaceutical product.121 In contrast, in the
context of small molecule drugs, a product is automatically deter-
mined to be “interchangeable” once structural identity and bioe-
quivalence are shown.122 For biologics, however, where seemingly
small changes in process may result in significant changes to the
properties of the molecule, “interchangeability” cannot be assumed—
hence the ostensibly more forgiving “biosimilar” standard.123
C. Preserving Incentives for Reference Biologic Product
Innovation
A pharmaceutical innovator is entitled to a period of exclusivity—
a time during which no other manufacturer may go to market with a
117. Id. § 262(k)(2)(A)(i)(III).
118. Id. § 262(k)(2)(A)(i)(IV).
119. Id. § 262(k)(2)(A)(i)(V).
120. SCIENTIFIC CONSIDERATIONS, supra note 26, at 11; see also 42 U.S.C.  § 262(k)(4).
121. See supra Part I.B; see also SCIENTIFIC CONSIDERATIONS, supra note 26, at 4–6 (noting
that minor structural differences can affect a protein’s safety, purity, or potency).
122. See ORANGE BOOK, supra note 82, at vi–vii.
123. 42 U.S.C. § 262(i)(2)(A).
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generic small molecule drug or a FOB.124 This period of exclusivity
rewards the innovator for the time and expense of developing the ref-
erence pharmaceutical product.
As discussed above in Part I.A, the cost to develop and produce a
traditional small molecule drug is significantly less expensive and
complicated than developing and producing a biologic drug. Al-
though exclusivity for the innovator is provided for both small mole-
cule drugs (i.e., through the Hatch Waxman Act) and for RBPs (i.e.,
through the BPCIA), the terms for these exclusivity periods are quite
different. The BPCIA gives due weight to the massive investment re-
quired to develop a RBP by providing exclusivity periods that protect a
RBP innovator’s ability to recover that investment.125 No FOB applica-
tion may be filed until four years after a RBP has been approved,126
and no FOB application may be approved until twelve years after ap-
proval of the RBP.127 A RBP may be entitled to another six months of
market exclusivity if the manufacturer has conducted the additional
studies required to support pediatric use.128 A RBP manufacturer is
thus guaranteed a minimum of twelve years of market exclusivity dur-
ing which no FOB may be marketed regardless of whether the RBP’s
patent protection extends to cover that entire time period.129
The Hatch Waxman Act also provides a similar data exclusivity
period for new drugs, although the shorter period of exclusivity re-
flects the typically less complicated development of the small mole-
124. See 21 U.S.C. § 355(c)(3)(E)(ii) (2006); 42 U.S.C. § 262(k)(7).
125. 42 U.S.C. § 262(k)(7).
126. Id. § 262(k)(7)(B). A RBP that has been designated for treatment of a rare disease
or condition is entitled to seven years exclusivity. See 21 U.S.C. § 360cc(a); see also 42 U.S.C.
§ 262(m)(2)(B) (providing seven years six months exclusivity when approved for pediatric
use).
127. Id. § 262(k)(7)(A).
128. Id. § 262(m)(2).
129. There has been some debate regarding whether the twelve-year “exclusivity” pe-
riod granted to the RBP in section (k)(7)(A) refers to “market” exclusivity or “data” exclu-
sivity. That is, some parties have argued that an application may be approved prior to the
expiration of the twelve years if the section (k) applicant submits its own clinical data,
rather than relying on the data submitted to gain approval of the RBP. Letter from Sen.
Kay R. Hagan et al. to Margaret Hamburg, Comm’r, U.S. Food & Drug Admin. (January 7,
2011), available at http://www.hpm.com/pdf/1-7-11%20Senate%20Biologics%20letter
%20to%20FDA.pdf. Other parties have argued that the twelve-year period provides market
exclusivity, in that no section (k) application may be approved, regardless of whether it
relies on clinical data from the RBP. Letter from AARP et al. to Margaret Hamburg,
Comm’r, U.S. Food & Drug Admin. (January 21, 2011), available at http://www.hpm.com/
pdf/generics%20biosimilars%20letter.pdf. Regardless of the interpretation, the practical
outcome is effectively twelve years of market protection, as the cost to a section (k) appli-
cant to conduct its own clinical studies most likely would be cost prohibitive.
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cule drug than that of the RBPs.130 For example, it may rely on fewer
preclinical and clinical trials for safety and efficacy. While generic
manufacturers may borrow the innovator’s clinical trial data under
the Hatch Waxman Act, a generic manufacturer must wait five years
after the approval of the new innovator drug before filing an applica-
tion that relies on such data for approval.131 The data exclusivity pe-
riod, if effective, provides market protection from generic
competition. Without access to the innovator’s data, a generic manu-
facturer would have to run its own clinical trials, and the high costs of
clinical trials deter market entry.
D. Encouraging Follow-on Biologic Applicants
Because the costs to develop and produce generic versions of
traditional small molecule drugs differ from those associated with the
production of biologics, the exclusivity period provided by the Hatch
Waxman Act for a generic small molecule product and by the BPCIA
for a FOB also differ. The Hatch-Waxman Act provides a 180-day mar-
ket exclusivity period for the first approved generic small molecule
drug product.132 By contrast, the BPCIA statute encourages FOB ap-
plications by awarding a longer market exclusivity period for the first-
approved interchangeable FOB.133 That is, no subsequent inter-
changeable FOB for a particular RBP may be approved for commer-
cial marketing until the earliest of several events:
• “[One] year after the first commercial marketing of the first
interchangeable” FOB;134
• Eighteen months after a final court decision on all patents in
a patent infringement action filed against the FOB applicant,
or dismissal of that action;135
• Forty-two months after approval of the first interchangeable
FOB if the FOB applicant was sued for infringement and the
suit is ongoing;136 or
130. See, e.g., PhRMA Press Release, supra note 9.
131. 21 U.S.C. § 355(c)(3)(E)(ii) (2006).
132. Id. § 355(j)(5)(B)(iv).
133. 42 U.S.C. § 262(k)(6) (2006 & Supp. IV 2011).
134. Id. § 262(k)(6)(A).
135. Id. § 262(k)(6)(B).
136. Id. § 262(k)(6)(C)(i).
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• Eighteen months after approval of the first interchangeable
FOB if the FOB applicant has not been sued for patent
infringement.137
By providing this longer period of market exclusivity for the first
interchangeable FOB, the FDA encourages companies to invest
money and resources in the development of FOBs.
E. Patent Protection and Disputes
The BPCIA also expressly addresses the issue of patent protec-
tion. A patent provides its owner with the right to exclude others from
making, using, or selling the patented invention.138 When a RBP inno-
vator obtains a patent for a biologic, or for the process that creates the
biologic, the RBP innovator is entitled to a certain number of years of
patent protection. During that period of patent protection, compa-
nies may not manufacture, sell, offer to sell, use, or import the bio-
logic or process without a license from the RBP.139 Given that
development of a RBP may take many years, and that a patent applica-
tion need not be filed until it is “reduced to practice,”140 the period of
patent and market exclusivity does not necessarily coincide. Market
exclusivity provisions are intended to ensure that an innovator’s in-
vestment is rewarded regardless of patent protection—given that the
scope, validity, and enforceability of patents can be challenged via ex-
pensive and burdensome litigation.141 Moreover, depending on the
137. Id. § 262(k)(6)(C)(ii). The exclusivity provision for a first generic small molecule
applicant (ANDA applicant) reflects the relatively lighter burden of an ANDA filer. That is,
the first successful ANDA applicant who makes a “Paragraph IV” certification that the ref-
erence drug holder’s patents were invalid or not infringed is entitled to only 180 days of
market exclusivity as opposed to the eighteen months of exclusivity granted to an inter-
changeable FOB section (k) applicant. 21 U.S.C. § 355(j)(5)(B)(iv).
138. 35 U.S.C § 271(a) (2006).
139. Generally, a patent provides at least twenty years of protection from the date of
the earliest filed nonprovisional application to which the patent claims priority. 35 U.S.C.
§ 154(a). That patent term may be increased by means of a patent term adjustment
(“PTA”), which is granted due to delays on the part of the Patent Office during prosecu-
tion. Id. § 154(b). In addition, a patent may be granted a patent term extension (“PTE”)
for a limited period of the delay caused by the FDA regulatory approval process to compen-
sate for time lost to seeking FDA approval. Id. § 156. This PTE is limited to a period of five
years. Id.
140. As discussed infra Part VI, enactment of the America Invents Act, Pub. L. No. 112-
29, 125 Stat. 284 (2011), which changes U.S. patent law such that an inventor who is “first
to file” for patent protection has superior rights in the claimed invention, may push RBP
innovators to file the patent applications earlier, or at least provisional patent applications,
so as to preserve their rights.
141. See, e.g., PRICEWATERHOUSECOOPERS LLP, 2011 PATENT LITIGATION STUDY: PATENT
LITIGATION TRENDS AS THE “AMERICA INVENTS ACT” BECOMES LAW (2011), available at http:/
1054 UNIVERSITY OF SAN FRANCISCO LAW REVIEW [Vol. 46
scope of the RBP innovator’s patent protection, a FOB applicant may
infringe on the RBP innovator’s patent rights by attempting to de-
velop a FOB.142 The BPCIA sets out a general framework for identify-
ing patent disputes and penalizes incomplete disclosures of potential
patent coverage.143 This encourages early identification and resolu-
tion of such disputes.
In marked contrast to the manner in which patent disputes are
identified and resolved in connection with the ANDA process for ge-
neric drugs, the BPCIA does not provide a public registry listing the
patents that apply to particular RBPs.144 An ANDA applicant can refer
to the FDA’s “Orange Book,” which lists patents for products ap-
proved under an NDA.145 An ANDA applicant is required to disclose
information to the reference product holder only if the applicant is
filing a “Paragraph IV” certification, under which the applicant chal-
lenges the scope, validity, or enforceability of the patent or patents
listed in the Orange Book for the reference product.146 The BPCIA,
on the other hand, provides for a timed exchange of information, ini-
tiated by the FOB applicant, who must provide the RBP innovator
with access to highly confidential manufacturing information.147
Upon submitting a FOB application to the FDA, a FOB applicant
has twenty days in which to provide the RBP innovator with confiden-
tial access to a copy of the FOB application and detailed information
regarding the FOB applicant’s manufacturing process.148 Upon re-
ceipt of such confidential access, the RBP innovator has sixty days to
produce to the FOB applicant a list of any patents, owned or exclu-
sively licensed by the RBP innovator, which it believes covers the RBP,
its manufacturing process, and/or its methods of use for which it re-
/www.pwc.com/us/en/forensic-services/publications/assets/2011-patent-litigation-study.
pdf.
142. Arguably, such attempts to develop a FOB are protected from patent infringe-
ment claims under the safe harbor provision, if conducted for the sole purpose of ob-
taining data reasonably related to the preparation of a submission for regulatory approval.
See 35 U.S.C. § 271(e)(1).
143. 42 U.S.C. § 262(l) (2006 & Supp. IV 2011).
144. Id. § 262(l)(3).
145. ORANGE BOOK, supra note 82, at ADA1–ADA207.
146. 21 U.S.C. § 355(j)(2) (2006).
147. 42 U.S.C. § 262(l).
148. Id. § 262(l)(2). The confidential information is provided to the RBP innovator’s
outside counsel, one in-house counsel, and a representative of a patent exclusively licensed
by the RBP innovator. See id. § 262(l)(1)(B)(ii)–(iii). Failure to provide the confidential
information provides the RBP innovator the ability to file a declaratory judgment suit. See
id. § 262(l)(9)(C).
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ceived FDA marketing approval.149 The FOB applicant then has sixty
days following the receipt of said list to provide the RBP innovator
with a list of the patents it believes covers the RBP, its manufacturing
process, and/or its methods of use for which it received FDA market-
ing approval. It must also provide: (1) a representation that it will not
market the FOB until the expiration of each of the RBP innovator’s
patents that it believes cover the RBP, its manufacture, or its use; (2) a
detailed statement as to why the FOB and its use and manufacture do
not infringe any of the RBP patents; and/or (3) a detailed statement
as to why the RBP patents are not valid or are not enforceable.150 The
RBP innovator subsequently has sixty days to provide the factual and
legal basis of infringement.151 Within fifteen days of the communica-
tions between the RBP innovator and FOB applicant, the parties must
negotiate the patents to be litigated.152 If the parties agree, the RBP
innovator has thirty days from the date of agreement to bring suit.153
If there is no agreement, then the parties exchange a list of patents
that each believes should be litigated.154 The RBP innovator then has
thirty days from the date of exchange to bring suit.155 Failure of the
RBP innovator to meet the statutory deadlines may preclude it from
asserting its patents against the proposed FOB at issue or may limit
the potential damages available.156
As further discussed below, this process and the potential preclu-
sive effect of choices, in terms of which patents to list and which to
litigate, makes it vitally important—even imperative—for both the
RBP innovator and the FOB manufacturer to be prepared with com-
prehensive and detailed information about patent coverage.
149. Id. § 262(l)(3)(A). Patents not included in the list, but that exist at that time, may
not be asserted in litigation against that FOB applicant. See 35 U.S.C. § 271(e)(6)(C).
150. 42 U.S.C. § 262(l)(3)(B)(i)–(ii). The FOB applicant also must respond to any of-
fer to license patents from the RBP innovator. See id. § 262(l)(3)(B)(iii).
151. Id. § 262(l)(3)(C).
152. Id. § 262(l)(4).
153. Id. § 262(l)(6)(A). The RBP innovator may add to the suit any newly issued or
exclusively licensed patent upon proper notice to the FOB applicant. Id. § 262(l)(7).
154. Id. § 262(l)(5)(B).
155. Id. § 262(l)(6)(B).
156. See 35 U.S.C. § 271(e)(6)(A)–(B) (providing a reasonable royalty as the sole and
exclusive remedy for infringement of patents for which the RBP innovator did not assert
within thirty days); see also 42 U.S.C. § 262(l)(6).  The language of the statute states that the
sponsor “shall bring an action” within 30 days. Id. Some commentators have interpreted
the statute as barring late assertions of patents by the RBP innovator if statutory deadlines
are not met.
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V. Food and Drug Administration Draft Guidance in
Implementing a Tiered Approach to Follow-on
Biologics Approval
In February 2012, the FDA issued three draft guidance docu-
ments designed to implement the BPCIA.157 The guidance documents
provide a stepwise approach to the demonstration of biosimilarity and
likewise detail the FDA’s review of proposed biosimilar FOBs. In addi-
tion, the documents provide an in-depth review of the general scien-
tific principles used to determine biosimilarity.158
While much of the guidance documents delve into specific scena-
rios and necessary tests to establish biosimilarity, the FDA generally
discusses the importance of a direct comparison between the FOB and
the reference product (i.e., the reference product is used in the same
tests as the FOB).159 The guidelines discuss a tiered approach under
which an applicant would first adduce analytical studies which demon-
strate that the biological product is highly similar in terms of struc-
ture: (1) primary amino acid sequence; (2) modification to amino
acids; (3) higher order structure (i.e., protein folding); and (4) qua-
ternary structure (i.e., interactions of subunits).160 Animal studies will
assess toxicity. Comparative human pharmacokinetic studies then will
demonstrate that the FOB and the RBP act in the same manner in a
human population. Finally, immunogenicity studies will show that the
FOB does not create unanticipated and potentially harmful immune
responses in patients.
The FDA does not provide product-class specific guidance on
how to demonstrate bioequivalence. The guidance documents do en-
courage frequent interaction between the FDA and the proposed FOB
developer (“sponsor”) in order to negotiate and agree upon the test-
ing necessary to demonstrate bioequivalence. Sponsors should meet
early with FDA. At that time the sponsor can provide the FDA with a
proposed plan for its development program, “manufacturing process
information (including planned methodology and assay validation),
157. QUALITY CONSIDERATIONS, supra note 31; SCIENTIFIC CONSIDERATIONS, supra note
26; U.S. DEP’T OF HEALTH & HUMAN SERVS. ET AL, GUIDANCE FOR INDUSTRY ON BIOSIMILARS:
QUESTIONS AND ANSWERS REGARDING IMPLEMENTATION OF THE BIOLOGICS PRICE COMPETI-
TION AND INNOVATION ACT OF 2009, DRAFT GUIDANCE (2012), available at http://www.fda.
gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM27
3001.pdf [hereinafter QUESTIONS AND ANSWERS].
158. QUALITY CONSIDERATIONS, supra note 31; SCIENTIFIC CONSIDERATIONS, supra note
26; QUESTIONS AND ANSWERS, supra note 157.
159. QUALITY CONSIDERATIONS, supra note 31, at 9.
160. SCIENTIFIC CONSIDERATIONS, supra note 31, at 7, 9–10.
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and preliminary comparative analytical data with the reference prod-
uct.”161 The FDA contemplates working with sponsors to evaluate that
proposed plan and to frame the requirements for showing biosimi-
larity and interchangeability.
VI. Biologics and the America Invents Act
On September 16, 2011, President Obama signed into law AIA.162
Though the new patent law does not explicitly address biologics, it
affects every area of innovation and patent protection. It makes sweep-
ing changes to U.S. patent law attempting to harmonize it with inter-
national patent law. Perhaps the most significant change is the AIA’s
incorporation of a “first to file” standard for patent protection—a de-
parture from the “first to invent” standard previously applied.163 Sum-
marized below are some of the most significant changes to patent law
implemented by the AIA and the manner in which those changes
might affect patent practice relating to biologics.
A. Novelty, Obviousness, and the First to File System
To be patentable, an invention must be novel—it cannot have
been previously described or used by others.164 In addition, it must
not be obvious in light of prior art already known.165 Prior art encom-
passes written publications, such as patents and articles, as well as pre-
vious uses of the invention or something very similar to the
invention.166 For example, similar to the law prior to the AIA, an in-
vention may be found to be unpatentable as obvious if components of
the invention are disclosed in several different pieces of prior art (i.e.,
a previous patent and a published article), and it would have been
routine to combine those components to create the claimed
invention.
One of the most substantial changes implemented by the AIA is
that both novelty and obviousness are determined as of the effective
filing date of the patent application.167 This departs from the previous
161. QUESTIONS AND ANSWERS, supra note 157, at 4.
162. Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284 (2011).
163. See infra Part VI.A.
164. 35 U.S.C. § 102 (2006).
165. Id. § 103.
166. Id. § 102 (defining disclosures that constitute prior art).
167. The effective filing date is the actual filing date or the filing date of the earliest
application to which the patent or application is entitled to claim priority. § 3(b), 125 Stat.
at 286–87 (amending 35 U.S.C. § 102(d)).
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standard, which utilized the date of the invention.168 This change
builds consistency between U.S. and international patent law, where
globally the individual or entity that is first to file for patent protection
has priority (superior rights) over others with respect to the claimed
invention.169
The AIA does preserve the one-year grace period for disclosures
made by the inventor, or an entity that obtained their information
from the inventor, such that an inventor who files for patent protec-
tion in November 2011 is not barred by its publication of the inven-
tion in December 2010.170 Disclosure of the invention or of
information that makes the invention obvious by a third party that did
not receive the information from the inventor invalidates prior art if it
occurs at any time prior to the inventor’s filing.171
Changing from the first to invent to a first to file as a basis for
priority172 is intended to provide greater certainty for inventors that
their patent will not be invalidated by someone who claims an earlier
date of invention.173 This change in the law, however, is likely to in-
crease pressure on inventors of biologics. A biologic inventor will want
to file for patent protection as soon as possible, to preserve exclusive
rights to their innovation. It may take a significant amount of time,
however, to fully and completely characterize an innovative biologic
or particular formulation for administering a biologic to patients. It
can be argued that a first to file system will put additional pressure on
companies seeking patent protection for biologics. Also, as discussed
in more detail herein, the challenges of scaling-up production, pre-
paring formulations that exhibit the desired stability both in vitro and
in vivo, and designing molecules that exhibit the desired
pharmacokinetics when administered to a subject, can be more com-
plicated and time-consuming for biologics than for small molecule
drugs. Thus, it can be envisioned that the increased importance of
early filing under the AIA may impose a higher hurdle on a biologic
inventor than did the pre-AIA criterion of a “first to invent” patent
system on a biologic inventor.
168. § 3(b)–(c), 125 Stat. at 285–87 (amending 35 U.S.C. §§ 102–103).
169. See § 3(o), 125 Stat. at 293 (providing a sense of Congress’ rationale for the AIA).
170. § 3(b), 125 Stat. at 285–87 (amending 35 U.S.C. § 102).
171. Id.
172. The first to file system will be implemented eighteen months after enactment of
the Act. § 3(e)(3), 125 Stat. at 288.
173. See § 3(o), 125 Stat. 293 (providing a sense of Congress’ rationale for the AIA).
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B. Written Description and Enablement Requirements
Notwithstanding the new focus on the date of filing for patent
protection, the AIA does not change the burdens placed on an inven-
tor by the “written description” and “enablement” requirements
under the U.S. patent law. To satisfy these requirements, an inventor
must provide not only a comprehensive, definite, and detailed
description of her invention, but also must provide sufficient informa-
tion to enable a “person skilled in the [relevant] art . . . to make and
use the [invention].”174
To satisfy the written description and enablement require-
ments,175 an inventor is required to provide a comprehensive descrip-
tion of the compound for which patent protection is sought. This can
be particularly challenging for the biologics’ inventor. While it may be
fairly straightforward to provide a description of a single biologic mol-
ecule (i.e., a protein therapeutic or monoclonal antibody) and to pro-
vide initial studies showing efficacy for certain indications, it may take
several years to explore what changes can be made to the molecule to
improve or preserve function. Similarly, characterizing the complete
spectrum of diseases for which the biologic may have therapeutic ben-
efits, developing a stable formulation, and developing large scale cul-
ture conditions may take several years. Obtaining patent protection is
desirable for a RBP innovator in order to protect the investment of
work spent determining all variations of a biologic (to identify and
describe sequencing and structural variations that have pharmaceuti-
cal utility), all indications, formulations, and culture conditions by ob-
taining patent protection. If the biologic is not adequately protected
by patent, then many if not all of these aspects are potential routes for
a design-around (a FOB that is just different enough to avoid the
RBP’s patent protection).
In some cases, the reference company might not choose to pro-
vide any public disclosure about the biologic until a good portion of
this characterization has been accomplished. Or, in some cases, a
company may choose to use provisional patent application to protect
the biologic.176 For example, a provisional application may be filed
providing an initial disclosure of at least some aspects such as the
chemical composition, early animal testing, and data relating to thera-
peutic indications for a biologic. If after one year, the research has not
174. 35 U.S.C. § 112 (2006).
175. Id.
176. Id. § 119(e).
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progressed to the point where the written description can encompass
claims for desired embodiments, such as, but not limited to, a relevant
number of bioequivalent molecules, the most important therapeutic
indications, formulations, and/or production of the biologic, that
provisional application can be abandoned. If additional experimental
results become available during the pendency of the first provisional
filing, then additional provisional applications containing the new
data may be filed. Subsequently, these applications can be abandoned
and refiled as necessary during the development and characterization
process before converting the provisional application(s) to a U.S. non-
provisional or PCT international patent application.177
Alternatively, the developer of a biologic may choose to file sepa-
rate patent applications for the various improvements to the initial
product. For example, a first patent application may cover the com-
pound and the initial therapeutic indications; a second patent appli-
cation may cover additional therapeutic applications; and a third
patent application may cover the formulation.
These various filing strategies are, however, very similar to filing
strategies required under pre-AIA law.
C. New Proceedings for Challenging or Reviewing Pending and
Issued Patents
The AIA also makes sweeping changes to procedures available for
attacking or reviewing patent applications and issued patents. Prior to
the AIA, proceedings available for challenging patent applications or
patents included ex parte citation of prior art in an application,178 or ex
parte reexamination proceedings,179 both of which are still available
under the patent statute. The AIA replaces inter partes reexamination
proceedings180 with inter partes review,181 discussed in more detail
below.
These new avenues for critical assessment of patents and pending
applications should improve the quality of issued U.S. patents. The
new procedures do not mitigate the burdens on a biologic patent ap-
plicant created by the juxtaposition of the need to fully characterize
177. Id. § 119(e)(1).
178. Id. § 301 (providing for citation of prior art to the USPTO).
179. Id. §§ 302–307 (providing for citation of prior art to the USPTO and ex parte
reexamination).
180. Id. §§ 311–318 (providing for inter partes reexamination).
181. Leahy-Smith America Invents Act, Pub. L. No. 112-29, § 6(a), 125 Stat. 284, 299
(2011) (amending the rules for inter partes review).
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biologic compounds with the new urgency to file as soon as possible.
The FDA does provide a RBP innovator (or, in some circumstances, a
third party such as an aspiring FOB applicant) with procedures for
challenging patent applications or patents that are believed to be
based on the invention of someone other than the applicant, or are
otherwise invalid for lack of novelty, or for failure sufficiently to de-
scribe or teach the claimed invention. A biologic inventor who has
been “scooped” by an earlier patent application filing may challenge
the filer’s rights. An applicant who filed too early—before knowing
enough about the claimed invention to satisfy written description re-
quirements—may also lose priority if the patent is ruled invalid.
1. Derivation Proceedings
The AIA’s first to file system is qualified by the rule that a patent
to a claimed invention will not be valid if the invention is “derived”
from another. The AIA provides for derivation proceedings,182 which
will replace current interference practice.183 Such derivation proceed-
ings must be filed within one year of publication of the petitioner’s
claim to the same or substantially the same invention as the earlier
filed, allegedly derived invention.184 The Director of the Patent Office
then institutes derivation proceedings if the required standards are
met.185 The AIA also provides for a civil derivation proceeding under
35 U.S.C. § 135, which may be filed later—within one year after the
issuance of the patent on the allegedly derived invention.186
Given the potential time lag between biologic innovation and the
ability fully to describe and claim a biologic invention with specificity
sufficient to support a patent application, the derivation proceeding is
a potential “fall back” for the biologic innovator who believes that an-
other has filed for patent protection for the invention. It will be im-
portant for companies producing biologics to diligently monitor
182. § 3(h), 125 Stat. at 288 (amending 35 U.S.C. § 291). The rules governing deriva-
tion proceedings come into effect eighteen months after enactment of the AIA. § 3(k), 125
Stat. at 291.
183. Under the current patent laws, an interference can be declared by the USPTO
and/or a party where the claims of two applications and/or an application and an issued
patent are the same. 35 U.S.C. § 135. Such proceedings provide a forum to determine
whom first invented the claimed invention; the first to invent is awarded priority and that
party’s patent will issue.
184. § 3(h), 125 Stat. at 288.
185. As of the writing of this Article, draft rules relating to derivation practice have
been provided by the USPTO for public comment. See USPTO, http://www.uspto.gov (last
visited May 10, 2012).
186. § 3(h), 125 Stat. at 288.
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prosecution of potentially relevant patent applications by competitors
in order to determine whether those applications include “derived”
claims.
2. Post-Grant Review and Inter Partes Review
One of the most important changes implemented by the AIA is
the post-grant review proceeding.187 These proceedings are con-
ducted by the Patent Trial and Appeal Board and provide a forum
much like the opposition proceedings, which occur in Europe. The
post-grant review may be filed on the basis of alleged prior art that
anticipates the invention or renders it obvious, or on the basis that the
specification does not provide adequate written description or enable-
ment for the invention as claimed.188 The post-grant review must be
filed within nine months after the patent is granted.189
Inter partes review proceedings190 are available after a Post-Grant
Review Proceeding is terminated (or nine months after a patent is
granted, whichever is later). Inter partes review may be based “only on a
ground that could be raised under section 102 or 103 [anticipation or
obviousness] and only on the basis of prior art consisting of patents or
printed publications.”191
3. Pre-Issuance Submissions
The AIA also provides for a new procedure under which any
party may submit prior art to the PTO so that the patent examiner can
consider such information in its determination as to whether a patent
should be issued.192 Such art must be submitted within certain time
frames during prosecution of the application.193 A potential chal-
187. § 6(d), 125 Stat. at 305 (amending post grant review proceedings at 35 U.S.C.
§§ 321–329). The post-grant review proceeding will take effect one year after enactment of
the AIA on any patent or application with an effective date on or before the one-year after
enactment date. § 6(f)(2)(A), 125 Stat. at 311.
188. § 6(d), 125 Stat. at 306 (noting that post grant review may be initiated on any
ground that could be raised under paragraph (2) or (3) of section 282(b), which relates to
invalidity of the patent or any claim).
189. Id.
190. § 6(a), 125 Stat. at 299 (amending 35 U.S.C. §§ 311–319 and renaming Chapter
31 from “optional inter partes reexamination procedures” to “inter partes review”).
191. Id. (amending 35 U.S.C. § 311(b)).
192. § 8(a), 125 Stat. at 315 (codifying preissuance submissions by third parties at 35
U.S.C. § 122(e)).
193. The submission is to be filed along with a statement of relevance of the art submit-
ted, and is to be filed by the earlier of: (1) a Notice of Allowance; or (2) the later of six
months after publication or the date of a first substantive rejection of the claims by the
USPTO. Id.
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lenger thus must diligently monitor prosecution of pending applica-
tions. It should also carefully consider whether the prior art at issue
might be more effectively presented in civil invalidity proceedings.
Once prior art is submitted during prosecution, a later civil challenge
on the basis of that art (if the patent issues) is significantly weaker
than if the prior art had not been before the Patent Office.
4. Supplemental Examination Available to Patent Applicant
The AIA’s new supplemental examination procedure provides a
means by which applicants may submit additional information to the
PTO after issuance of their patent.194 Such disclosures include publi-
cations previously not disclosed, or potential mischaracterizations of a
claimed invention made during prosecution of the application, or
other disclosures, that during a litigation proceeding could be found
to render a patent unenforceable due to inequitable conduct. The
AIA provides that “a patent shall not be held unenforceable on the
basis of conduct relating to information that was not considered, was
inadequately considered, or was incorrect in a prior examination of
the patent if the information was considered, reconsidered, or cor-
rected during a supplemental examination of the patent.”195 The abil-
ity to request supplemental examination may reduce the number of
inequitable conduct challenges in litigation by providing applicants
the opportunity to correct potential omissions or mischaracterizations
that may have occurred during prosecution.
D. Effect of New Review Proceedings on Patent Validity Litigation
The new post grant review and inter partes review proceedings pur-
suant to the AIA will be much more like civil patent infringement liti-
gation than PTO reexamination proceedings under the previous
patent law. The AIA proceedings can be filed by any party that is not
the owner of the patent and are conducted independently of the pat-
ent examiner.196 If any of these new post-publication proceedings
under the AIA are filed before civil patent litigation, the civil litigation
will be stayed, and the Patent Office’s decision may ultimately be bind-
194. § 12, 125 Stat. at 325 (codifying supplemental examination proceedings at 35
U.S.C. § 257).
195. Id.
196. § 6(d), 125 Stat. at 305 (amending post-grant review proceedings under 35 U.S.C.
§§ 321–329); § 6(a), 125 Stat. at 299 (recodifying “inter partes reexamination” as “inter partes
review proceedings” under 35 U.S.C. §§ 311–319).
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ing on civil litigants.197 Conversely, if a civil court case challenging
patent validity is filed first, none of the new post-publication proceed-
ings are available.198 The new review proceedings thus provide a new
forum for challenging a competitor’s patent, but require a high level
of preparedness and diligence in monitoring patent applications and
patents.
E. Additional Aspects of the America Invents Act Relating to
Patent Litigation
The AIA also redefines several defenses to patent infringement
claims. In conjunction with the new patent review procedures de-
scribed above, these changes heighten the importance of prepared-
ness and early attention to strategy—both for a reference biologic
inventor and for a FOB applicant seeking to design around or to inval-
idate the inventor’s patent protection. Among the changes that will
affect planning for reference biologic innovators and aspiring FOB
applicants are:
• Elimination of the “best mode” defense: Past law provided an
invalidity defense for failure to disclose the best mode of prac-
ticing an invention known to the inventor at the time of filing
for patent protection.199 An inventor is still required to de-
scribe, in the patent itself, the best manner of making a
claimed compound or device, or the best way to practice a
claimed method. Now, however, an inventor’s failure to dis-
close that “best mode” is not a defense to patent infringe-
ment.200 The AIA thus renders a reference biologic
innovator’s patent less vulnerable to an invalidity attack in in-
fringement litigation against a FOB applicant;
• Enlargement of the “prior use” defense: In the past, a patent
claiming a method, i.e., for formulating a biologic, could be
attacked as invalid on the basis a commercial use within the
United States at least one year before the patent’s effective
filing date.201 The AIA provides that this “prior use” defense is
no longer restricted to method claims, but can be used to in-
197. § 6(a), 125 Stat. at 299; § 6(d), 125 Stat. at 305.
198. Counterclaims of invalidity are not subject to this restriction. § 6(a), 125 Stat. at
299; § 6(d), 125 Stat. at 305.
199. 35 U.S.C. § 112 (2006).
200. § 15(a), 125 Stat. at 328 (amending 35 U.S.C. § 282(3) and specifically stating that
failure to disclose the best mode will not be grounds for cancellation).
201. 35 U.S.C. § 273(b).
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validate claims for compositions or devices as well.202 The AIA
also now includes commercial uses outside the United
States.203 Development and use of biologics outside the
United States now may constitute a “prior use” defense to pat-
ent infringement allegations; and
• Expansion of the scope of potentially invalidating prior art:
Past law provided that a patent was invalid on proof that the
invention was known or used in the United States, or de-
scribed in a patent or printed publication, in the United
States, more than one year before the effective filing date of
the patent.204 The AIA expands invalidity defenses under sec-
tion 102 to include defenses based on prior knowledge, use,
or description in a patent or printed publication anywhere in
the world.205 This provision makes it easier for a FOB appli-
cant to attack a reference biologic innovator’s patent. It also
highlights the importance of conducting thorough and broad
prior art searches, both for the patentee and an accused
infringer.
VII. Strategies for Players in the Biologics Market: How Best
to Negotiate the New Legal Landscape
The new law and regulatory framework for reference biologics,
FOBs, and patent law, urge that both a RBP innovator and a FOB
applicant take several steps. These include developing strategies for:
(1) addressing the FDA application pathway, (2) the disclosure re-
quirements, (3) patent prosecution and monitoring, (4) patent port-
folio management, and (5) patent enforcement to be positioned for
marketplace success under the new law. The new law heightens the
importance for RBP innovators and FOB applicants to be armed with
complete information (or as complete information as feasibly can be
obtained) about prior art, pending U.S. and foreign patent applica-
tions, issued patents, and development and uses of biologic products
both in and outside the United States. The following sections describe
strategies for both RBPs seeking to protect and maximize gain from
their innovation and for FOBs seeking to carve out a piece of the bio-
logics market to protect their innovations and processes.
202. § 5(a), 125 Stat. at 297 (amending 35 U.S.C. § 273 to include machines, manufac-
tures, and compositions of matter).
203. § 3(b), 125 Stat. at 285 (amending 35 U.S.C § 102).
204. 35 U.S.C. § 102.
205. § 3(b)(1), 125 Stat. at 285 (amending 35 U.S.C. § 102).
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A. Strategies for a Reference Biologic Product Innovator
1. Review Patent Portfolio
To best position itself in view of the new approval pathway, a RBP
innovator should carefully review its patent portfolio to determine
which patents and patent applications could cover the RBP it intends
to market. Once identified the RBP innovator should assess the poten-
tial strengths and weaknesses of the identified patents and applica-
tions to best protect its product while asserting patent infringement
claims or countering allegations of invalidity or unenforceability.
Once an application is filed with the FDA by a FOB and notice is pro-
vided to the RBP innovator of the application, the RBP innovator only
has sixty days to respond to the notice by requesting additional infor-
mation and by providing a list of patents that it believes the FOB ap-
plicant may infringe if it makes, uses, sells, or imports the FOB in the
United States. Early review of its patent portfolio is critical to allow a
RBP innovator properly to respond under the tight deadlines imposed
by the BPCIA, focusing on the patents that it believes are infringed by
each FOB applicant, the patents it is willing to license to each FOB
applicant, and the arguments it will make against any assertions of
non-infringement, unenforceability, and invalidity. The RBP innova-
tor must be prepared with information to make decisions about which
of its patents are strong enough to assert against each FOB applicant.
The RBP innovator also should keep continuation applications
pending, if possible, for each of its key patents relating to its product
and the methods of making and using the product. This enables it to
maintain options for pursuing additional claims or perhaps a continu-
ation-in-part application as needed to cover follow-on products as they
are developed. Continuation applications provide the RBP innovator
an opportunity to continue to claim additional subject matter that was
disclosed, but not claimed in, the issued patents.206 By keeping contin-
uation applications pending, the RBP innovator may prevent FOB ap-
plicants from “designing around” the issued claims. In addition, the
RBP innovator should consider whether a narrowing reissue or reex-
amination process would be effective to solidify its rights in view of
relevant prior art. If in analyzing its patent portfolio, the RBP innova-
tor identifies certain patent claims that arguably are overly broad and
are likely to be challenged by the FOB applicant based on prior art
references, the RBP innovator can preempt such attacks by seeking to
206. 35 U.S.C. § 120.
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amend the claims through a narrowing reissue or reexamination pro-
cess to a more appropriate claim scope.
2. Expand Patent Protection for Broader Exclusivity
The RBP innovator should consider whether it can preempt po-
tential competition from a FOB applicant that designs molecules
which fall outside the RBP innovator’s patent claims, but nonetheless
have substantially the same therapeutic utility by considering whether
to file patent applications for such “design-around” molecules. Some
of those molecules may be new chemical entities with a different
amino acid sequence than the RBP. In this manner, the RBP innova-
tor can strengthen its patent position relative to the FOB developer
while also establishing a new patent term of twenty years for the de-
sign around molecules.
Some of the new molecules may act as “biobetters” with enhanced
biological or therapeutic efficacy relative to the reference product. A
RBP innovator with a therapeutic protein product may file new patent
applications disclosing the amino acid sequence of therapeutic pro-
teins with conservative amino acid substitutions at specific amino acid
residues (such as alanine for leucine), if such substitutions result in
enhanced efficacy. In another example, the RBP innovator may substi-
tute asparagine or threonine amino acid residues at selected positions
in the protein to facilitate single or multiple glycosylations of the pro-
tein, thereby prolonging the half-life of the therapeutic protein or
possibly enhancing receptor binding. This results in a molecule with
enhanced biological activity—a biobetter. Once a patent application
for a biobetter publishes, the publication acts as a novelty-destroying
event for a potential FOB developer pursuing the same protein. Alter-
natively, if the RBP innovator makes a strategic decision not to pursue
patents on such proteins because it does not want to commit to the
research and development expense of developing design around pro-
teins, the RBP innovator may decide to publish an article. This has the
potential of affecting the proposed patent application’s novelty and
perhaps rendering its claims (and the claims of other parties) obvious.
3. Identify the Competition and Potential Follow-on Biologic
Applicants
The RBP innovator should know its competition by identifying,
investigating, and monitoring: potential FOB applicants, their com-
mercial activities, regulatory filings, issued patents, published patent
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applications, and new partnerships and joint ventures with other
companies.
Routinely monitoring the published patent applications and is-
sued patents of competitors enables a RBP innovator to gain insight
into the potential FOB applicants’ patent portfolios. This approach
provides several advantages to the RBP innovator. For example, the
RBP innovator may have a superior insight into the prior art, having
already prosecuted its own patent applications. The RBP innovator
may decide to send relevant prior art to the potential FOB applicant
company and its patent counsel in the United States, or perhaps di-
rectly to a Patent Office, thereby slowing patent prosecution or per-
haps destroying patentability of some claims.
As discussed above the AIA provides several new routes for such
submissions. An applicant should consider making its submission of
relevant art with comments to focus the patent examiner. Further, if
material prior art sent to a potential FOB applicant or its patent coun-
sel is not disclosed to the USPTO the FOB developer and its patent
counsel may be subject to charges of inequitable conduct and patent
invalidity.207 This could seriously impede a FOB applicant that may
not have the resources to fight such a battle. Further, the RBP innova-
tor could decide to oppose an allowed patent of a FOB developer in
Europe or use the new post grant review procedures in the United
States. By performing such patent surveillance on competitors who
may become FOB applicants, the RBP innovator can achieve tactical
advantages and be better prepared to respond when a FOB applica-
tion is filed.
B. Strategies for Follow-on Biologic Developers
1. Familiarity with Swift Biologics Price Control and Innovation
Act Pathway Timing and Costs
FOB developers—potential FOB applicants—are motivated to be
the first to file a FOB application because of the potential for signifi-
cant profits and limited exclusivity (for a first “interchangeable”
FOB). However, these companies must prepare for significant up-
front costs of conducting patent due diligence on the RBP innovator
and preparing arguments of patent invalidity for the RBP innovator’s
patents. The potential FOB applicant must also prepare for the costs
associated with the defense of patent infringement litigation. A FOB
developer also must be familiar with the requirements for a FOB ap-
207. 37 C.F.R. § 1.56 (2011); 37 C.F.R. pt. 11.
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plication, which, as discussed above, are far more stringent and exten-
sive than those applied to generic drugs.
2. Due Diligence on the Reference Biologic Product Innovator’s
Patents
Because there is no Orange Book equivalent that a potential FOB
applicant can consult to determine what patents protect the RBP and
the methods of making it, the FOB developer must perform its own
due diligence on the RBP to make this determination and to identify
the relevant patents’ expiration dates. Due to the short response turn-
around time after the RBP innovator provides a listing of patents be-
lieved to cover the FOB, an applicant should prepare an assessment of
the validity and enforceability of any RBP innovator patents that it
determines could protect the RBP before filing its FOB application.
Such diligence investigation should include a review of the remaining
patent terms, the scope of the issued claims, the arguments made by
the RBP innovator during prosecution of the patent application that
might lead to estoppel, related pending and published applications
that may protect the RBP, and whether all required maintenance fees
have been paid. It is also important that the FOB applicant determine
whether any licenses are necessary from a third party in order to mar-
ket its FOB.
The FOB developer should consider commissioning an invalidity
search and a non-infringement and invalidity opinion letter from a
patent attorney for the claims of the RBP innovator’s patents covering
the RBP. If resources are limited, the potential FOB applicant must
perform its own search for prior art, arming itself with knowledge to
decide whether there are viable arguments with respect to non-in-
fringement, validity, or unenforceability of the RBP innovator’s pat-
ents. A FOB applicant must prepare for the accelerated litigation
schedule triggered by the submission of a FOB application. If it is not
possible to make valid arguments against the RBP innovator patents,
then the FOB applicant must wait to market its FOB until after the
RBP innovator’s patents expire.
If the FOB developer discovers invalidating prior art, it will be
better prepared to make arguments of patent invalidity when the RBP
innovator asserts its patents against the FOB. The FOB applicant also
should consider whether to provide this prior art anonymously with
statements concerning its materiality to the USPTO for consideration.
The FOB applicant should also consider whether to file a request for
reexamination of the RBP innovator’s patents, using prior art patents
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or printed publications, which have bearing on patentability of the
relevant claims. If the RBP innovator’s patent is within nine months of
grant, the FOB applicant should consider an inter partes review proce-
dure as an alternative.208
3. Review Intellectual Property Portfolio
The FOB applicant should carefully review its own patent portfo-
lio to ensure that it has adequately protected its proprietary methods
of manufacturing the FOB because the BPCIA requires that a FOB
applicant’s manufacturing methods be revealed to the RBP innovator.
This warrants serious consideration because the BPCIA appears to
mandate extensive disclosures of what would otherwise be considered
highly sensitive and confidential trade secrets. Assurances of confiden-
tiality may not provide adequate protection of a FOB developer’s core
business. The potential FOB applicant should also consider whether
there is room to maneuver and design around the RBP innovator’s
patents.
4. Seek Patent Protection for New Molecules or Methods of
Manufacture
If the FOB applicant is precluded from seeking patent protection
for its FOB as a composition of matter because it falls within the
claims of the RBP innovator’s patent, the FOB developer should con-
sider ways to design around the claims of the RBP innovator’s patent.
If the claims of the RBP innovator’s patent are broader than the
amino acid sequence of the RBP protein, then there may not be much
room to design around the claims to create a new protein that may act
as a biobetter. This is because the new protein also may fall within the
scope of the patent claims. The FOB developer also should consider
whether to file patent applications on its own methods of manufactur-
ing the FOB or attempt to maintain these methods as a trade secret,
especially in view of the disclosure requirement to the RBP innovator
described above.209
If the RBP innovator’s patent claims protect a few conservative
amino acid substitutions of the reference product protein but not the
substitution of amino acid residues with arginine, threonine, serine,
or tyrosine for post-translational modifications, such as glycosylation
or phosphorylation, then the FOB applicant should decide whether to
208. See supra Part VI.C (discussing the AIA’s provisions for such review).
209. See supra Part IV.E.
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create these molecules and examine their biological activity and toxic-
ity through research and development. In this case, the FOB applicant
may want to quickly file a provisional patent application covering
these molecules that may be new chemical entities. Subsequent con-
version of that patent application could eventually provide twenty
years of patent protection. Subsequent research and development
could demonstrate that these molecules may prove to have a greater
biological activity and lower toxicity. In such an instance, the mole-
cules could be deemed to be biobetters. As such, these molecules may
be considered new molecules, which would be the subject of a new
biologics license application rather than a FOB application.
C. Hypothetical
This section provides hypothetical examples of both the perspec-
tives of a RBP company and of a FOB company in terms of specific
biologics and patent strategy pursuant to the BPCIA and the AIA.
Adipolyse Pharmaceutical Company (“Adipolyse”) is a reference
product company with a reference product called liposin, a peptide of
twelve amino acids which functions to metabolize fat (lipolysis) and to
reduce weight. The amino acid sequence of liposin is: Alanine – Leu-
cine – Aspartic acid – Alanine – Tyrosine – Histidine – Glutamic acid
– Proline – Leucine – Valine – Aspartic acid – Valine. This sequence is
abbreviated as follows, wherein each amino acid residue is numbered
from 1 at the N-terminus (the amino terminus, in this case alanine) to
12 at the C-terminus (Carboxy terminus, in this case valine) of the
peptide (SEQ ID NO:1):
1 2 3 4 5 6 7 8 9 10 11 12
Ala–Leu–Asp–Ala–Tyr–His–Glu–Pro–Leu–Val–Asp–Val
Adipolyse has a patent claiming the liposin peptide sequence,
which expires in 2014. Adipolyse also holds patents for therapeutic
methods of administering liposin for weight reduction. Adipolyse
does not have patent protection for the method of making liposin as
liposin is synthesized using the known method of solid phase synthe-
sis. The FDA approved liposin to treat obesity. In view of the explod-
ing epidemic of obesity in the United States and Europe, and the
associated risks of diabetes, cardiovascular disease, and musculoskele-
tal disorders, Adipolyse has a billion dollar market.
1072 UNIVERSITY OF SAN FRANCISCO LAW REVIEW [Vol. 46
Adipolyse’s issued patent protects the liposin peptide sequence
shown above, as well as a slightly different sequence (SEQ ID NO:2):
1 2 3 4 5 6 7 8 9 10 11 12
Ala–Ala*–Asp–Ala–Tyr–His–Glu–Pro–Leu–Val–Asp–Val
SEQ ID NO:2 has an alanine (Ala) for leucine (Leu) substitution
at position 2. Adipolyse could not obtain broader patent protection
for the composition patent as the patent examiner would not budge—
only allowing the two sequences that Adipolyse demonstrated were ef-
fective in metabolizing fat. Adipolyse is considering a biosimilars ap-
plication to the FDA for SEQ ID NO:2 and does not expect any
problems due to the conservative amino acid substitution at position
2.
Although Adipolyse believes the validity of its composition patent,
it has a continuation application pending and is considering filing a
continuation-in-part application to cover slightly different sequences
with modifications at positions 1, 9, 10, and 11. It aims to prevent
patent protections for possible design around molecules by biosimilar
applicant or other competitor.
Slim N Fit is a small company with limited resources. Slim N Fit’s
business plan is to gain market share in the field of diabetes by devel-
oping peptides that increase metabolism, reduce body weight, and in-
crease the amount of brown fat which is more metabolically active
than other fat. Slim N Fit is aware of Adipolyse’s patent covering SEQ
ID NOs: 1 and 2, and it employs a team of peptide chemists and mo-
lecular biologists to develop efficient methods of making these se-
quences in bacteria at a fraction of the cost of the solid phase
synthesis techniques employed by Adipolyse. Slim N Fit also con-
ducted due diligence on Adipolyse and found prior art published in
Japan two years before the priority date of Adipolyse’s patent that Slim
N Fit believes would invalidate Adipolyse’s patent.
Slim N Fit decided to file biosimilar applications with the FDA for
both SEQ ID NOs: 1 and 2, although it decided to first file a patent
application on its method of making these sequences. During re-
search and development, Slim N Fit made additional sequences that
are variations of SEQ ID NOs: 1 and 2. These are SEQ ID NOs: 3, 4,
and 5:
SEQ ID NO:3
1 2 3 4 5 6 7 8 9 10 11 12
Ala–Leu–Asp–Ala–Tyr–His–Glu–Pro–Leu–Val–Asn*–Val
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SEQ ID NO: 4
1 2 3 4 5 6 7 8 9 10 11 12
Ala–Leu–Asn*–Ala–Tyr–His–Glu–Pro–Leu–Val–Asp–Val
SEQ ID NO:5
1 2 3 4 5 6 7 8 9 10 11 12
Ala–Leu–Asn*–Ala–Tyr–His–Glu–Pro–Leu–Val–Asn*–Val
Slim N Fit discovered that substitution of an asparagine (Asn) for
aspartic acid (Asp) at position 3 and/or 11 to create a glycosylation
site permitted one or more sugar residues to be added to the mole-
cule during biosynthesis. These molecules containing sugars were fifty
percent more biologically active to burn fat, were resistant to being
degraded in the blood, and were able to convert white fat cells to
brown fat cells.
In addition to filing a patent application claiming methods to
manufacture SEQ ID NOs: 1, 2, 3, 4, and 5, Slim N Fit also filed a
provisional application to protect the compositions of SEQ ID NOs: 3,
4, and 5. Slim N Fit believes SEQ ID NOs: 3, 4, and 5 are new composi-
tions of matter, which are biobetters compared to SEQ ID NOs: 1 and
2. It also believes that they may obtain twenty years of patent protec-
tion, thereby gaining market share and avoiding Adipolyse’s patent.
However, since Slim N Fit’s resources are limited, it plans to try to
piggyback on the safety and efficacy data in Adipolyse’s FDA applica-
tion to see if it can push SEQ ID NOs: 3, 4, and 5 through regulatory
approval as biosimilars to SEQ ID NOs: 1 and 2. During that process,
Slim N Fit is seeking a strategic partnership through a license with a
competitor of Adipolyse to develop clinical data for a regulatory sub-
mission. In this manner it will be prepared to file a BLA if the FDA
does not accept SEQ ID NOs: 3, 4, and 5 as biosimilars to SEQ ID
NOs: 1 and 2.
Conclusion
In view of the new law and the recently issued FDA guidance,210
both innovator companies, and companies making FOBs must care-
fully plan patent strategy, while addressing the nuances of regulatory
210. Patient Protection and Affordable Care Act, Pub. L. No. 111-148, §§ 7001–7003,
124 Stat. 119, 804–21 (2010); Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125
Stat. 284 (2011); SCIENTIFIC CONSIDERATIONS, supra note 26.
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approval requirements. The intersection of the new patent law and
the BPCIA’s provisions for FOBs is an emerging area of the law that
will undoubtedly be tested and defined in the federal courts, as RBP
and FOB companies seek to protect their innovations and return on
investment, even as there is increasing societal pressure to hasten de-
livery of therapeutic biologics at lower cost to patients and the health
care system.
